These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27919895)

  • 21. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class 1 integrons in urinary isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Southern China during the past five years.
    Sun J; Zheng F; Wang F; Wu K; Wang Q; Chen Q; Yu S; Rui Y
    Microb Drug Resist; 2013 Aug; 19(4):289-94. PubMed ID: 23573964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Plasmid-mediated cephalosporinase among extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae].
    Wang QT; Liu YM; Wang H; Sun HL; Chen MJ; Du XL
    Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):487-90. PubMed ID: 15312399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
    Karaiskos I; Souli M; Giamarellou H
    Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City.
    Landman D; Babu E; Shah N; Kelly P; Bäcker M; Bratu S; Quale J
    J Antimicrob Chemother; 2010 Oct; 65(10):2123-7. PubMed ID: 20667885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of carbapenemases, extended spectrum β-lactamases, quinolone resistance and aminoglycoside resistance determinants in carbapenem-non-susceptible Escherichia coli from a teaching hospital in Chongqing, Southwest China.
    Zhang C; Xu X; Pu S; Huang S; Sun J; Yang S; Zhang L
    Infect Genet Evol; 2014 Oct; 27():271-6. PubMed ID: 25107431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.
    Olsen SC; Carlson SA
    Int J Antimicrob Agents; 2015 Jan; 45(1):76-8. PubMed ID: 25459738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and characterization of extended-spectrum beta-lactamase (ESBL)- and CMY-2-producing Escherichia coli isolates from healthy food-producing animals in Tunisia.
    Ben Sallem R; Ben Slama K; Sáenz Y; Rojo-Bezares B; Estepa V; Jouini A; Gharsa H; Klibi N; Boudabous A; Torres C
    Foodborne Pathog Dis; 2012 Dec; 9(12):1137-42. PubMed ID: 23194332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and molecular characterization of extended-spectrum β-lactamase (ESBL) and plasmidic AmpC β-lactamase (pAmpC) producing Escherichia coli in dogs.
    Aslantaş Ö; Yilmaz EŞ
    J Vet Med Sci; 2017 Jun; 79(6):1024-1030. PubMed ID: 28450661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Occurrence of Extended-Spectrum β-lactamase-Producing Escherichia coli in Finnish Food-Producing Animals.
    Päivärinta M; Pohjola L; Fredriksson-Ahomaa M; Heikinheimo A
    Zoonoses Public Health; 2016 Dec; 63(8):624-631. PubMed ID: 27215423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.